A61P 5/02
Drugs for disorders of the endocrine system: of the hypothalamic hormones
Official title: of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
A61P5/02 (Drugs for disorders of the endocrine system: of the hypothalamic hormones) appears on 569 US grants and 752 published applications in this corpus.
Search patents in A61P- Granted patents
- 569
- Published applications
- 752
- Assignees
- 350
- Inventors
- 1,540
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 3 | 0 |
| 1981 | 0 | 0 |
| 1982 | 3 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 3 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 6 | 0 |
| 1997 | 6 | 0 |
| 1998 | 20 | 0 |
| 1999 | 14 | 0 |
| 2000 | 9 | 0 |
| 2001 | 20 | 6 |
| 2002 | 23 | 32 |
| 2003 | 23 | 41 |
| 2004 | 26 | 60 |
| 2005 | 27 | 45 |
| 2006 | 30 | 48 |
| 2007 | 28 | 53 |
| 2008 | 30 | 48 |
| 2009 | 17 | 52 |
| 2010 | 20 | 33 |
| 2011 | 30 | 34 |
| 2012 | 30 | 30 |
| 2013 | 26 | 26 |
| 2014 | 24 | 20 |
| 2015 | 23 | 30 |
| 2016 | 26 | 38 |
| 2017 | 15 | 22 |
| 2018 | 18 | 18 |
| 2019 | 15 | 20 |
| 2020 | 14 | 19 |
| 2021 | 9 | 10 |
| 2022 | 6 | 18 |
| 2023 | 7 | 19 |
| 2024 | 8 | 13 |
| 2025 | 5 | 9 |
| 2026 | 3 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Specification of functional cranial placode derivatives from human pluripotent stem cells5 May 2026US 12,618,044 B2Memorial Sloan Kettering Cancer Center
- Solid dosage formulations of an orexin receptor antagonist14 Apr 2026US 12,599,610 B2Merck Sharp & Dohme Corp.
- Reprogramming of lipid metabolism to inhibit T cell senescence and enhance tumor immunotherapy31 Mar 2026US 12,590,309 B2Saint Louis University
- GhR-binding peptide and composition comprising same16 Sep 2025US 12,415,834 B2PeptiDream Inc.
- Cortistatin analogues for the treatment of inflammatory and/or immune diseases13 May 2025US 12,297,294 B2Bcn Peptides, S.A.
- Dissolvable microneedle patch for large molecule therapeutic delivery17 Sep 2026US 2026/0273253 A1Maman Biomedical Inc.
- Solid dosage formulations of an orexin receptor antagonist23 Jul 2026US 2026/0207619 A1Merck Sharp & Dohme Corp.
- Ghr-binding peptide and composition comprising same23 Jul 2026US 2026/0209276 A1PeptiDream Inc.
- Steroid as a modulator of gabaa receptor11 Jun 2026US 2026/0158043 A1Umecrine Cognition AB
- Compositions and methods for treating acromegaly28 May 2026US 2026/0144852 A1Camurus AB
Most cited
By later US patents
- 3-heteroaryl-2-indolinone compounds for the treatment of disease265US 5,792,783 ASugen, Inc. · 1998
- 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease169US 5,883,113 ASugen, Inc. · 1999
- 3-(4'-dimethylaminobenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease168US 5,886,020 ASugen, Inc. · 1999
- 3-(2'-halobenzylidenyl)-2-indolinone compounds for the treatment of disease165US 5,834,504 ASugen, Inc. · 1998
- Polymeric delivery formulations of leuprolide with improved efficacy158US 6,773,714 B2Atrix Laboratories, Inc. · 2004